Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abexinostat and Ibrutinib in DLBCL and MCL
NCT03939182Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2019
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abexinostat in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started May 2019; status: completed.
02
Drugs
abexinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03939182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03939182.